Cancer Clinical trials office (CCTO) - Tisch Cancer Institute affiliated Icahn School of Medicine at Mount Sinai, USA.
Assistant Professor of Psychiatry Penn State College of Medicine, Milton S Hershey Medical Center, Hershey, PA, USA.
Psychiatry Res. 2021 Mar;297:113742. doi: 10.1016/j.psychres.2021.113742. Epub 2021 Jan 19.
The objective of this study is to compare game-based digital therapeutic device and other DHI like (smartphone apps, wearable technologies) for ADHD with the current pharmacological and behavior therapy. The FDA has approved a game-based digital therapeutic device - EndeavorRx, for the treatment of ADHD in pediatric patients belonging to the age group of 8-12 years old. This has been primarily recommended for the treatment of inattentive or combined-type ADHD who have demonstrated an attention issue. This is the first game-based therapeutic device to be approved by the FDA for any type of condition. According to the FDA, this has been shown to improve attention which is measured by computer-based testing. Objective: The objective of this study is to compare a game-based digital therapeutic device and other DHI (smartphone apps, wearable technologies) with the current pharmacological and behavior therapy used in the treatment of ADHD.
本研究旨在比较基于游戏的数字治疗设备与其他 ADHD 数字健康干预（智能手机应用程序、可穿戴技术）与当前药物治疗和行为疗法的效果。FDA 已批准一款基于游戏的数字治疗设备——EndeavorRx，用于治疗 8-12 岁儿童患者的 ADHD。该设备主要推荐用于治疗注意力不集中或混合型 ADHD，这些患者表现出注意力问题。这是 FDA 批准的首款用于任何疾病的基于游戏的治疗设备。根据 FDA 的说法，该设备已被证明可以通过计算机测试来改善注意力。目的：本研究旨在比较基于游戏的数字治疗设备与其他 ADHD 数字健康干预（智能手机应用程序、可穿戴技术）与当前药物治疗和行为疗法的效果。
